In this regard, estrogen-receptor-positive (ER+) invasive ductal cancers (IDCs), the most common type of breast cancer, are commonly treated with selective estrogen receptor modulators (SERMs), which have been shown in multiple studies to improve clinical outcomes [5,6]. Here, ESR1 is linked to breast cancer.